What is the 4T score in heparin‑induced thrombocytopenia (HIT)?

The 4T Score in Heparin-Induced Thrombocytopenia

The 4T score is a validated clinical prediction tool that stratifies patients into low, intermediate, or high probability of HIT based on four clinical criteria: Thrombocytopenia (degree of platelet fall), Timing of platelet count fall, Thrombosis or other sequelae, and oTher causes of thrombocytopenia. This scoring system is essential for determining which patients require further laboratory testing and alternative anticoagulation 1.

Components of the 4T Score

The 4T score evaluates four domains, each scored 0-2 points, for a maximum total of 8 points 2:

1. Thrombocytopenia (Platelet Count Fall)

• 2 points: Platelet fall >50% AND nadir ≥20 × 10⁹/L
• 1 point: Platelet fall 30-50% OR nadir 10-19 × 10⁹/L
• 0 points: Platelet fall <30% OR nadir <10 × 10⁹/L

2. Timing of Platelet Count Fall

• 2 points: Clear onset between days 5-10, or ≤1 day with recent heparin exposure (within 30 days)
• 1 point: Consistent with days 5-10 fall but not clear; onset after day 10; or fall ≤1 day with heparin exposure 30-100 days ago
• 0 points: Platelet fall <4 days without recent exposure

3. Thrombosis or Other Sequelae

• 2 points: New thrombosis, skin necrosis, acute systemic reaction after IV heparin bolus
• 1 point: Progressive or recurrent thrombosis, non-necrotizing skin lesions, suspected thrombosis (not proven)
• 0 points: None

4. oTher Causes of Thrombocytopenia

• 2 points: No other apparent cause
• 1 point: Possible other cause
• 0 points: Definite other cause present

Risk Stratification and Clinical Implications

Low probability (0-3 points): The negative predictive value is exceptionally high at 99.8% 3. In patients with a low 4T score, HIT is effectively ruled out, and further testing should be avoided 1. These patients can safely continue heparin if clinically indicated 1.

Intermediate probability (4-5 points): Approximately 14% of these patients have confirmed HIT 3. These patients require immediate discontinuation of heparin and laboratory testing with immunoassays 1.

High probability (≥6 points): Approximately 64% have confirmed HIT 3. These patients require immediate heparin cessation and initiation of non-heparin anticoagulation while awaiting confirmatory testing 1.

Critical Management Algorithm Based on 4T Score

For Low 4T Score (≤3):

• Do not order laboratory HIT testing 1
• Continue heparin if clinically indicated
• No need for alternative anticoagulation
• This approach prevents unnecessary testing in 75% of suspected cases 4

For Intermediate/High 4T Score (≥4):

1. Immediately discontinue all heparin products (including flushes) 1, 5
2. Start therapeutic-dose non-heparin anticoagulant (argatroban, bivalirudin, fondaparinux, or direct oral anticoagulants) 1
3. Order immunoassay testing (PF4/heparin antibody ELISA or chemiluminescence assay) 1
4. Do not give platelet transfusions unless life-threatening bleeding 2
5. Do not start warfarin until platelets recover to >150 × 10⁹/L 2

Based on Immunoassay Results:

If immunoassay is negative:

• Intermediate 4T score: Stop non-heparin anticoagulant, resume heparin if needed 1
• High 4T score: Stop non-heparin anticoagulant, resume heparin if needed (rarely, repeat testing may be warranted) 1

If immunoassay is positive:

• Continue therapeutic-dose non-heparin anticoagulant 1
• Avoid all heparin products
• Continue until platelet count recovers, then transition to warfarin with minimum 5-day overlap 2

Common Pitfalls and Caveats

Critical care populations present unique challenges: The 4T score shows variable interobserver agreement in ICU settings, particularly for the "oTher causes" domain 6, 7. Thrombocytopenia is extremely common in critically ill patients (20-45%), but confirmed HIT occurs in only 0.4% 7. When applying the 4T score in ICU patients, consider heparin exposure prior to ICU admission, as this information significantly impacts scoring accuracy 6.

Overtesting is a major problem: Studies show 48-60% of HIT testing occurs in patients with low 4T scores, leading to unnecessary costs exceeding $100,000 per institution and inappropriate use of expensive alternative anticoagulants 8, 9. Implementing electronic medical record-based 4T calculators can reduce inappropriate testing by 75% 8, 4.

The "oTher causes" domain generates the most disagreement among clinicians 6. In critically ill patients, multiple potential causes of thrombocytopenia often coexist (sepsis, medications, liver disease), making this assessment particularly challenging.

Timing matters for accurate scoring: The 4T score performs best when calculated at the time of clinical suspicion, not retrospectively 6. Real-time scoring by bedside clinicians may differ from expert adjudication, emphasizing the need for careful, systematic application.